different kidney diseases being targeted so got to be cautious about comparing , but this asset (68% proteinurya reduction against placebo which is huge!) and the Novartis news yesterday that Fabhalta got fda accelerated approval for Iga nepropathy, 38% reduction proteinuria vs placebo just serves to highlight imo the relatively small effect of the dimx asset as a protein in urine reducer (17% vs placebo in phase 2).
Banter and general comments, page-25
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $231.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11061 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 2000 | 1 |
View Market Depth
| Last trade - 10.02am 16/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |
Day chart unavailable